ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ADMA Biologics reports robust Q4 results and outlines growth strategies

ADMA Biologics demonstrated strong financial performance and strategic progress in Q4 2022, positioning the company for growth.
The company's focus on operational excellence, product performance, and market acceptance underpins its growth strategy.
Challenges in achieving profitability and market expansion are being addressed through strategic initiatives and operational enhancements.
Opportunities in label expansions, plasma donor targeting, and manufacturing scale-up offer avenues for sustained growth and market differentiation.

ADMA Biologics reports record revenue growth and profitability in Q1

ADMA Biologics demonstrated strong financial performance in Q1 2023, with notable revenue growth and achieving adjusted EBITDA profitability for the first time.
While facing regulatory and operational challenges, the company is strategically positioned for growth, focusing on immune globulin products and patient outcomes.
Management's commitment to innovation, cost efficiencies, and market expansion underscores ADMA's dedication to driving revenue growth and achieving profitability.

ADMA Biologics reports robust Q2 earnings and growth outlook

ADMA Biologics delivered strong financial results, raised revenue guidance, and showcased operational efficiency, positioning the company for sustained growth and market leadership.
The success of ASCENIV and the company's focus on plasma collection underscore ADMA's commitment to patient care, innovation, and social responsibility in the biologics sector.
While facing challenges in a competitive landscape, ADMA has opportunities to expand market reach, increase awareness, and solidify its position as a unique player in the industry.
By balancing financial objectives with social impact goals and emphasizing market differentiation, ADMA can navigate challenges and leverage opportunities for long-term success and stakeholder value.

ADMA Biologics achieves profitability in Q3, poised for growth

ADMA Biologics delivered a strong performance in Q3 2023, achieving profitability for the first time and demonstrating robust revenue growth.
The company's focus on ASCENIV, gross margin improvement, and revenue guidance raise optimism for future prospects and market positioning.
While facing challenges in debt refinancing and patient activation, ADMA Biologics is well-positioned to capitalize on opportunities in product enhancement and market expansion.
Overall, ADMA Biologics' strategic initiatives and financial performance in Q3 indicate a positive trajectory for growth and profitability in the biologics market.

ADMA Biologics achieves positive earnings, focuses on innovation and growth

ADMA Biologics reported a strong financial performance in Q4 2023, achieving positive adjusted net income and cash flow. The company emphasized innovation, growth strategies, and operational efficiencies to drive future success.
While facing challenges in managing profitability and debt, ADMA Biologics is focused on maintaining a strong gross margin profile and developing products targeting specific infectious diseases. The company's commitment to shareholder returns and revenue growth presents opportunities for sustained success.
Overall, ADMA Biologics showcased resilience and strategic planning during the earnings call, with a clear focus on financial stability, innovation, and maximizing shareholder value. The company's positive outlook and growth initiatives position it well for future growth and market competitiveness.

ADMA Biologics reports robust Q1 earnings, eyes sustained growth

ADMA Biologics delivered strong financial performance in Q1 2024, showcasing revenue growth, profitability, and upwardly revised guidance for 2024 and 2025, underlining their growth potential.
The company's focus on innovation, efficiency, and niche markets, along with confidence in long-term growth initiatives, positions them well for sustained value creation and revenue growth beyond 2025.
While facing challenges in operational efficiency, market penetration, and post-2025 revenue growth, ADMA Biologics remains optimistic about growth opportunities and revenue expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Today, ADMA stock is a big mover as the company announced a very bullish FDA approval allowing the company to scale its core product. The post ADMA Stock: The Big FDA News Boosting ADMA Biologics Today appeared first on InvestorPlace.

ADMA Stock: The Big FDA News Boosting ADMA Biologics Today

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Adma Biologics (ADMA) Report Negative Q1 Earnings? What You Should Know

Boxlight

Verastem

Penny stocks are back in a big way; which 3 should you watch? The post Penny Stocks Are Back; Here's 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks Are Back; Here's 3 to Watch Right Now

The FDA has approved ADMA Biologics Inc's (NASDAQ: ADMA) expanded manufacturing process, enabling fractionation and purification of a 4,400-liter plasma pool to manufacture Intravenous Immune Globulin (IVIG). The 4,400-liter IVIG plasma pool scale for BIVIGAM will allow ADMA to expand its manufacturing plant's total processing capacity from 400,000 liters to an anticipated peak throughput of up to 600,000 liters.

ADMA Biologics Shares Jump On Increased Manufacturing Capacity For Intravenous Immune Globulin

The stock price of ADMA Biologics Inc (NASDAQ: ADMA) increased by over 20% pre-market. This is why it happened.

ADMA Stock: Over 20% Increase Pre-Market Explanation

After a painful two months, shareholders of ADMA Biologics (NASDAQ:ADMA) may finally have something the be happy about. The downtrend in the stock that began in February has ended.

ADMA Biologics Breaks Downtrend And May Rally

Poster Presentation Highlights the Unmet Patient Need and Medical Cost Burden Associated with Hepatitis B Infection

ADMA Biologics Announces Poster Presentation Highlighting Pharmacoeconomic Burden of HIV and HBV Infection in Sexual Assault Patients at the 2021 Academy of Managed Care Pharmacy Virtual Annual Meeting

ADMA Biologics recently reported a mixed Q4/2020 earnings with a slight miss on EPS and a slight beat on revenue. Consequently, ADMA has been under substantial selling pressure. The ongoing pandemic has disrupted the industry; however, ADMA was able to report record revenue and expects to report quarter-over-quarter revenue growth.

ADMA Biologics: Sell-Off Provides Buying Opportunity Ahead Of Projected Growth

ADMA continues to execute and delivered another great quarter. ADMA has improved its guidance with respect to profitability and plasma center developments.

ADMA Biologics: Continuing To Execute

ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q4 2020 Results - Earnings Call Transcript

Achieved Full Year 2020 Total Revenues of $42.2 Million, a 44% Increase Over Full Year 2019

ADMA Biologics Reports Fourth Quarter and Full Year 2020 Financial Results

Adma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

RAMSEY, N.J. and BOCA RATON, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Virtual Plasma Summit being held on Thursday, March 11, 2021, at 11:20 a.m. ET.

ADMA Biologics to Participate in the Jefferies Virtual Plasma Summit

Atea Pharmaceuticals

BioNTech SE

Lexicon Pharmaceuticals

Moderna

Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.

4 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Adma Biologics (ADMA) Upgraded to Buy: Here's Why

Achieved Fourth Quarter 2020 Preliminary Unaudited Total Revenues of $13.9 Million, the Highest Revenue Quarter for the Company Since Inception

ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2020 Revenues and Provides 2021 Strategic Outlook

ADMA has been overly chastised by the market, and its business is performing very well. At its current trading level, ADMA is trading at just about its enterprise value when considering the value of its portfolio of plasma collection centers, which will soon be 16.

ADMA Biologics: A Perfect Storm

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved transitional pass-through payment status and established a new reimbursement C-code, C9072, for ASCENIV which is effective January 1, 2021.

ADMA Biologics Receives Unique Temporary C-Code and Pass-Through Payment Status for ASCENIV™

ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

ADMA Biologics (ADMA) in Focus: Stock Moves 6.6% Higher

ADMA Biologics recently reported its Q3 earnings with a beat on EPS and revenue. In addition, the company reported encouraging commercial progress for its IVIG products despite the COVID-19 headwinds. Unfortunately, the healthcare sector is experiencing some selling pressure after the outcome of the U.S. presidential election, and ADMA is moving closer to 52-week lows.

ADMA Biologics: Another Quarter Of Progress And Another Dip To Buy

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2020 Virtual London Healthcare Conference on Tuesday, November 17, 2020, at 7:55 a.m. ET.

ADMA Biologics to Participate in Jefferies 2020 Virtual London Healthcare Conference

ADMA Biologics' (ADMA) CEO Adam Grossman on Q3 2020 Results - Earnings Call Transcript

Generated Total Revenues of $ 28. 3 Million for the First Nine Months of 2020 , Reflecting a 63 % Increase Over the Same Prior Year Period

ADMA Biologics Reports Third Quarter 2020 Financial Results and Business Highlights

Conference Call Scheduled for Thursday, November 5, 2020, at 4:30 p.m. ET Conference Call Scheduled for Thursday, November 5, 2020, at 4:30 p.m. ET

ADMA Biologics to Report Third Quarter 2020 Financial Results and Business Highlights on November 5, 2020

On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.

News for ADMA Biologics Stock (ADMA)